Zacks Research Has Positive Outlook of Prothena Q3 Earnings

Prothena Corporation plc (NASDAQ:PRTA) – Equities researchers at Zacks Research lifted their Q3 2026 earnings per share estimates for shares of Prothena in a report issued on Thursday, October 16th. Zacks Research analyst Team now expects that the biotechnology company will earn ($0.78) per share for the quarter, up from their prior estimate of ($0.87). The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share. Zacks Research also issued estimates for Prothena’s Q4 2026 earnings at $0.04 EPS and FY2026 earnings at ($2.42) EPS.

Several other research firms have also recently weighed in on PRTA. Royal Bank Of Canada lowered their price target on Prothena from $18.00 to $10.00 and set a “sector perform” rating on the stock in a report on Tuesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prothena in a report on Wednesday, October 8th. Piper Sandler lowered their price target on Prothena from $81.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, August 28th. JMP Securities lowered their price target on Prothena from $29.00 to $11.00 and set a “market outperform” rating on the stock in a report on Tuesday, September 2nd. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $18.00 price target on shares of Prothena in a report on Thursday, August 28th. Four investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $20.50.

Prothena Stock Down 1.7%

NASDAQ:PRTA opened at $9.92 on Monday. The business’s 50-day moving average price is $8.88 and its two-hundred day moving average price is $7.77. Prothena has a twelve month low of $4.32 and a twelve month high of $18.88. The stock has a market cap of $533.99 million, a P/E ratio of -1.76 and a beta of -0.11.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.75). The company had revenue of $4.42 million for the quarter, compared to analysts’ expectations of $5.36 million. Prothena had a negative return on equity of 62.17% and a negative net margin of 2,929.30%.

Hedge Funds Weigh In On Prothena

Large investors have recently modified their holdings of the company. GAMMA Investing LLC raised its holdings in shares of Prothena by 4,626.0% during the 1st quarter. GAMMA Investing LLC now owns 6,002 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 5,875 shares in the last quarter. Prospera Financial Services Inc purchased a new position in shares of Prothena during the 2nd quarter valued at about $61,000. Cambridge Investment Research Advisors Inc. purchased a new position in Prothena in the 1st quarter worth approximately $126,000. CWM LLC increased its stake in Prothena by 650.1% in the 3rd quarter. CWM LLC now owns 10,246 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 8,880 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in shares of Prothena by 571.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,709 shares of the biotechnology company’s stock worth $77,000 after buying an additional 10,815 shares during the last quarter. 97.08% of the stock is owned by hedge funds and other institutional investors.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.